Rosenbloom: Curb PBMs’ power
By Alan Rosenbloom
Letter to the Editor
The Washington Times
Despite the purported value of pharmacy benefit managers (PBMs), drug prices remain unaffordable for many Americans (“Prescription drug pricing reform must rein in pharmacy benefit managers,” Web, Oct. 18). As middlemen between the manufacturers, pharmacies and consumers, PBMs are notorious for abusive business practices that impact both patients’ wallets and their access to prescription drugs, while gouging unaffiliated pharmacies.
As Rep. Carter and Mr. Wilcox correctly note, PBMs process the vast majority of the nation’s prescription drugs. This undue concentration of market power means they can and do restrict consumer access to expensive drugs and cause delays in treatment, all so that affiliated pharmacies dispense and earn revenues while denying competing pharmacies access to high-margin drugs.
PBMs are not freestanding operations. They are part of huge health care conglomerates that dominate not only the PBM market, but a series of adjoining markets including health insurance, retail pharmacy, specialty pharmacy, mail-order pharmacy and long-term-care pharmacy. They have also become health care providers, which has allowed them to control the flow of medications. This anti-competitive behavior is clearly apparent in Express Scripts’ recent decision to reduce reimbursement rates for pharmacies in the TRICARE network, forcing veterans and their families to find alternate ways to access covered drugs — or simply pay for them out-of-pocket.
Small businesses, such as the community and long-term care pharmacies that are not part of these corporate behemoths, deserve protection from unfair trade practices. Consumers deserve more than the illusion of low costs at the price of easy access to essential medications.
To curb PBMs’ exploitative business practices, all stakeholders — including the Federal Trade Commission, Congress, the Biden administration and federal health departments — must focus on how these entities drive high drug prices, restrict access to essential medications and threaten unaffiliated pharmacies.
To view the original article click here.
Recent Posts
-
Rep. Beth Van Duyne: Congress can save seniors’ access to medications before it’s too late
Seniors in nursing homes across the country depend on round-the-clock care and medications, perhaps more than any other American patient population. In turn, the nursing homes and assisted living facilities that care for them depend on a small number of specialized long-term care (LTC) pharmacies to ensure their patients have access to the prescription meds they need.
-
Bill Aims to Offset Reimbursement Losses for Long-Term Care Pharmacies Catering to Nursing Homes
Starting in January, falling prices for costly drugs may strain long-term care pharmacies, but proposed legislation backed by advocacy groups aims to subsidize some of this loss. And nursing home advocacy groups are among those urging Congress to pass the Preserving Patient Access to Long-Term Care Pharmacies Act.
-
Drug pricing policy could jeopardize long-term care pharmacies, leaders contend
Senior living and care leaders have joined a coalition calling attention to a policy fix they say would address unintended consequences of Medicare Part D price negotiations that could shutter long-term care pharmacies.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.